BEARINGPOINT
3.3.2020 09:02:13 CET | Business Wire | Press release
Management and technology consultancy BearingPoint announced today that full-year 2019 revenues hit a record €780 million, a 6% increase from the previous year, due in particular to new revenue streams and innovative business services. The firm delivered projects for clients in over 70 countries. Bookings for 2019 came in at €949 million, which was up 15% compared to the prior year. The substantial growth in bookings points to a strong 2020. BearingPoint said its Strategy 2025, launched last year, has created a solid foundation for sustainable growth. To support growth, BearingPoint hired 1,400 people last year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200303005041/en/
“In 2019, we laid the foundation for the future of our firm by developing our Strategy 2025. Three major ambitions drive this strategy. One, we put people in the center. Two, we’re going to outperform the market every year. Three, we’re going to be within the top three players in selected areas we decide to play,” said Managing Partner Kiumars Hamidian. “Despite difficult market conditions in certain segments and market geographies, our firm proved to be resilient and able to grow. 2020 is all about the execution of our strategy. Our backlog is strong, the market conditions in most of our countries are promising, and team spirit is extremely high.”
Strategic growth and innovation
BearingPoint established Business Services as a separate unit at the beginning of 2019. Business Services provides IP-driven digital assets and managed services beyond SaaS. The firm also accelerated the growth of its software business by further verticalizing its two product lines: BearingPoint Beyond and BearingPoint RegTech. BearingPoint Beyond is a digital platform solution provider that helps organizations reinvent their business model and grow revenue by utilizing digital platforms and partner ecosystems. BearingPoint RegTech is a leading provider of innovative regulatory and risk technology solutions and launched an international “regulatory reporting factory” last year.
To support its overall growth objectives, BearingPoint also made a strategic move by acquiring Prederi, a leading consultancy focused on public services in the UK. With the acquisition, BearingPoint continued its growth strategy in selected markets with consultancies that are highly focused and strongly differentiated.
Once again, there was a strong focus on creating innovation. More than 130 ideas, startups, and initiatives were submitted to the firm’s “Hub of Innovation,” and over 20 minimum viable products (MVPs) were developed. Market observers again singled out BearingPoint in 2019 for its innovation and strengths, with 90 analyst recognitions and various awards.
Putting people in the center
As part of putting people at the center, one of the three core ambitions of its Strategy 2025, BearingPoint established a long-term incentive plan that rewards employee loyalty. The firm also established LGBTQ+ and All Inclusive communities and expanded its (Y)Our Ways program. BearingPoint’s (Y)Our Ways is about redesigning the way people work to achieve tangible business outcomes. It leverages IP, talent, and expertise. People-centric by design, (Y)Our Ways is transforming the way BearingPoint makes a difference for its people, clients, and ecosystems.
10 years of BearingPoint – 10 years of success
In 2019, BearingPoint celebrated 10 years of success as an independent, Partner-led management and technology consultancy by giving back to people, planet, and society in the biggest CSR campaign in the firm’s history. The #10DaysOfCaring campaign saw BearingPoint’s people across its offices worldwide participate in more than 150 different activities ranging from planting trees and cycling to work to donating blood and volunteering for local nonprofits. BearingPoint said that #10DaysOfCaring underlined the firm’s culture of teamwork, creativity, and a can-do attitude.
BearingPoint used the momentum from the campaign to start new initiatives, like launching new affinity networks. The firm also signed the UN Global Compact in 2019 and committed itself to the 10 underlying principles that include environmental and climate protection. One way BearingPoint showed its commitment was by making its business travel activities climate-neutral for all its business units globally.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business critical services to its clients supporting their business success. The third unit provides the software for successful digital transformation and regulatory requirements. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005041/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
